Harland C, Shah T, Webster A D, Peters T J
Division of Clinical Cell Biology, MRC Clinical Research Centre, Harrow, Middlesex, UK.
Clin Exp Immunol. 1988 Nov;74(2):201-5.
Dipeptidyl peptidase IV (DPIV), a T cell enzyme, has been implicated in the regulation of lymphocyte proliferation in response to lectins and allogeneic cells. A sensitive fluorimetric assay has been established for the enzyme and used to investigate DPIV activity, kinetics and the subcellular localization in lymphocytes from control subjects, cord blood and patients with common variable hypogammaglobulinaemia (CVH) and chronic lymphatic leukaemia (CLL). Using sucrose density gradient centrifugation and organelle marker enzyme assays, in conjunction with digitonin as a selective plasma membrane perturbant and diazotized sulphanilic acid as a non-permeant enzyme inhibitor, DPIV was shown to be a plasma membrane ecto-enzyme. A significant decrease in lymphocyte DPIV activity was observed in cord blood and in patients with CVH and CLL compared to controls. Kinetic analysis showed a marked decrease in the Vmax of lymphocyte DPIV from cord blood and patients with CVH and CLL compared to controls. The apparent Km for the substrate was unaffected in cord blood and patients with CLL. However, in patients with CVH the Km was significantly reduced. Various enzyme inhibitors showed no differences between control subjects and CVH lymphocyte activities. The decreased Km for DPIV provides further evidence for a stem cell defect rather than cell immaturity in CVH.
二肽基肽酶IV(DPIV)是一种T细胞酶,与淋巴细胞对凝集素和同种异体细胞反应的增殖调节有关。已建立了一种针对该酶的灵敏荧光测定法,并用于研究对照受试者、脐带血以及常见变异型低丙种球蛋白血症(CVH)和慢性淋巴细胞白血病(CLL)患者淋巴细胞中的DPIV活性、动力学和亚细胞定位。使用蔗糖密度梯度离心和细胞器标记酶测定法,结合洋地黄皂苷作为选择性质膜扰动剂以及重氮化磺胺酸作为非渗透性酶抑制剂,DPIV被证明是一种质膜外酶。与对照组相比,在脐带血以及CVH和CLL患者中观察到淋巴细胞DPIV活性显著降低。动力学分析表明,与对照组相比,脐带血以及CVH和CLL患者淋巴细胞DPIV的Vmax显著降低。脐带血和CLL患者中底物的表观Km未受影响。然而,CVH患者的Km显著降低。各种酶抑制剂在对照受试者和CVH淋巴细胞活性之间未显示出差异。DPIV的Km降低为CVH中的干细胞缺陷而非细胞不成熟提供了进一步证据。